comprehensive -WSS

comprehensive

author：focus 2025-09-06 03:33:47 - browse：5

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： New brain studies show LSD's effects on the brain in full color

WSS

After decades in use, heart stents finally beat placebo

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

FDA reorg will put new emphasis on investigations, sources say

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Medical school prerequisites are outdated

focus

comprehensive

focus

Activists slam private health insurers over coverage restrictions

New brain studies show LSD's effects on the brain in full color

Medicare details structure of new drug price negotiation program

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Apple is now the first public company to be valued at $3 trillion

Copay coupons to count toward deductibles, after Biden court move

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

As demand for Covid shots wanes, Moderna seeks its next success

Dewpoint Therapeutics lays off staff after losing partnerships

knowledge

New brain studies show LSD's effects on the brain in full color

Carbon Health diabetes program, a test of data

NIH director takes cautious approach to Biden drug pricing priority

Humana cuts profit projections as Medicare Advantage costs soar

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Elizabeth Holmes banned from government health programs

focus

focus

focus

focus